| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $138,377,121 ) (Continued on the next page) |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA288617 | TROP2-Directed CAR-NK Cells for the Immunotherapy of Pancreatic Cancer | 000 | 2 | NIH | 3/3/2025 | $333,518 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K01CA297060 | Decoding Mosaic Chromosomal Alterations in Lymphoid Malignancy Risk and Outcomes | 000 | 1 | NIH | 7/11/2025 | $192,240 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE030875 | Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers | 001 | 4 | NIH | 5/7/2025 | $55,614 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01DE030875 | Functional roles of GOF TP53 mutations in metastasis and immunosuppression of head and neck cancers | 000 | 4 | NIH | 3/10/2025 | $500,532 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | F31CA305956 | 129Xe Hyperpolarized Chemical Exchange Saturation Transfer (HyperCEST) MRI for Tracking Immunotherapy Delivery in the Lungs | 000 | 1 | NIH | 7/16/2025 | $37,613 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA301555 | Delivery optimization of a transarterial ablative therapy | 000 | 1 | NIH | 3/11/2025 | $536,836 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01EB034665 | Single-use Microfluidic Device for Radiopharmaceutical Production | 000 | 1 | NIH | 2/25/2025 | $574,632 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01EB034665 | Single-use Microfluidic Device for Radiopharmaceutical Production | 001 | 1 | NIH | 4/2/2025 | $0 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA287279 | Deciphering the structural determinants of response and resistance to HER2-targeted antibody-drug conjugates and tyrosine kinase inhibitors for HER2-mutant Non-Small Cell Lung Cancer | 000 | 1 | NIH | 3/19/2025 | $695,004 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R61DA058276 | Bayesian neurobehavioral phenotyping: from mechanism identification to personalized neuromodulation treatments | 001 | 2 | NIH | 7/28/2025 | $408,302 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R61NS140684 | Development and validation of a tumor-bearing model of oxaliplatin-induced neuropathy | 001 | 1 | NIH | 4/9/2025 | $408,277 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R61NS140684 | Development and validation of a tumor-bearing model of oxaliplatin-induced neuropathy | 001 | 1 | NIH | 4/9/2025 | -$408,277 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R61NS140684 | Development and validation of a tumor-bearing model of oxaliplatin-induced neuropathy | 000 | 1 | NIH | 1/31/2025 | $408,277 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA256006 | Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants | 003 | 5 | NIH | 7/25/2025 | $0 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA256006 | Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants | 004 | 5 | NIH | 7/25/2025 | $81,881 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA256006 | Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants | 002 | 5 | NIH | 5/22/2025 | $37,057 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA256006 | Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants | 001 | 5 | NIH | 5/2/2025 | $0 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA256006 | Glioma therapy with oncolytic adenoviruses and immunometabolic adjuvants | 000 | 5 | NIH | 2/18/2025 | $333,518 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299972 | Deregulation of Sulfatide Synthesis in the Development and Progression of Pancreatic Cancer Precursor Lesions | 000 | 1 | NIH | 3/1/2025 | $616,495 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | K99CA296780 | The role of oral microbiota in metastatic brain tumors | 000 | 1 | NIH | 3/10/2025 | $112,026 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AG067419 | Alzheimer's Disease Pathology in a Primate Model | 001 | 5 | NIH | 8/11/2025 | $57,502 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AG067419 | Alzheimer's Disease Pathology in a Primate Model | 000 | 5 | NIH | 2/14/2025 | $646,905 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA288901 | Proteomics-driven precision molecular mapping of patient tumors to preclinical models in lung cancer | 000 | 1 | NIH | 3/11/2025 | $244,228 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258788 | A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain | 001 | 4 | NIH | 5/22/2025 | $54,957 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258788 | A Comprehensive Clinical fMRI Software Solution to Enable Mapping of Critical Functional Networks and Cerebrovascular Reactivity in the Brain | 000 | 4 | NIH | 2/14/2025 | $494,624 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA256848 | Determining the optimal ion and fractionation scheme for the treatment of GBM in a comprehensive human organoid model | 000 | 5 | NIH | 2/14/2025 | $412,116 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01GM152497 | Computational toolkit for robust detection of genomic variation in human leukocyte antigen genes | 001 | 2 | NIH | 8/8/2025 | $29,259 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01GM152497 | Computational toolkit for robust detection of genomic variation in human leukocyte antigen genes | 000 | 2 | NIH | 3/5/2025 | $263,340 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | U01DE033330 | Advancing On-Slide and Optical Biopsy Tools to Detect High-Risk Oral Premalignancy | 003 | 3 | NIH | 7/29/2025 | $674,252 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AT012375 | Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults | 001 | 3 | NIH | 3/19/2025 | $0 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01AT012375 | Multi-site feasibility and acceptability of a faith-based mind-body intervention in Black adults | 000 | 3 | NIH | 1/29/2025 | $497,585 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA236905 | Molecular Understanding and Targeting of Determinant Factors in Gastric Tumorigenesis | 001 | 5 | NIH | 5/23/2025 | $37,057 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA269622 | An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma | 001 | 3 | NIH | 5/22/2025 | $46,421 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA236905 | Molecular Understanding and Targeting of Determinant Factors in Gastric Tumorigenesis | 000 | 5 | NIH | 3/3/2025 | $333,518 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R37CA269622 | An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinoma | 000 | 3 | NIH | 2/12/2025 | $417,797 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03DE033550 | Administrative Supplement for Probabilistic Deep Learning Cervical Lymph-Node Auto-Segmentation For Imaging-enhanced Evaluation of Extracapsular Extension Risk (PDL-CLASIFIER) | 002 | 2 | NIH | 7/23/2025 | $175,256 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03DE033550 | Administrative Supplement for Probabilistic Deep Learning Cervical Lymph-Node Auto-Segmentation For Imaging-enhanced Evaluation of Extracapsular Extension Risk (PDL-CLASIFIER) | 001 | 2 | NIH | 5/9/2025 | $16,200 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03DE033550 | Administrative Supplement for Probabilistic Deep Learning Cervical Lymph-Node Auto-Segmentation For Imaging-enhanced Evaluation of Extracapsular Extension Risk (PDL-CLASIFIER) | 000 | 2 | NIH | 3/18/2025 | $145,800 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269646 | Targeting ferroptosis in cancer therapy | 001 | 3 | NIH | 5/22/2025 | $49,400 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA269646 | Targeting ferroptosis in cancer therapy | 000 | 3 | NIH | 2/13/2025 | $444,596 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA270010 | Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer | 001 | 3 | NIH | 5/29/2025 | $47,386 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA270010 | Exploring novel strategies for immunoprevention of estrogen receptor negative breast cancer | 000 | 3 | NIH | 2/12/2025 | $426,474 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA288804 | A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy | 001 | 2 | NIH | 5/22/2025 | $18,933 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R21CA288804 | A Novel Strategy of Targeting Transmembrane Protein to Improve KRAS-targeted Therapy | 000 | 2 | NIH | 2/13/2025 | $170,405 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01NS117668 | Systematic dissection of function and mechanism of long non-coding RNAs in glioblastoma | 000 | 5 | NIH | 3/12/2025 | $364,500 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R03CA296049 | Targeting of E-cadherin-negative diffuse-type gastric cancer | 000 | 1 | NIH | 7/2/2025 | $163,500 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA299696 | Decoding the co-evolution of cancer subclones and their ecosystem in TNBC multi-organ metastasis | 000 | 1 | NIH | 3/12/2025 | $676,584 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01HL179815 | Deciphering the role of GFPT2 in radiation-induced cardiovascular disease | 000 | 1 | NIH | 7/18/2025 | $760,982 |
| | 2025 | 2025 | THE UNIVERISTY OF TEXAS M.D. ANDERSON CANCER CENTER | 1515 HOLCOMBE BLVD | HOUSTON | TX | 77030-4009 | HARRIS | USA | R01CA258917 | Mitochondrial heterogeneity as the origin of chemoresistance in pancreatic cancer | 001 | 5 | NIH | 5/23/2025 | $46,003 |
|
